150
Participants
Start Date
February 29, 2000
Primary Completion Date
August 31, 2018
Study Completion Date
August 31, 2018
Cyclophosphamide
1000 mg/m2 I.V. on day 1
Radiotherapy
The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.
Vincristine
1.4 mg/m2 (maximum single dose of 2 mg) I.V. on day 1
Prednisolone
50 mg/m2 orally daily for days 1 - 5
Rituximab
375 mg/m2 IV Infusion day 1
Auckland Hospital, Auckland
Prince of Wales Hospital, Randwick
Westmead Hospital, Wentworthville
Calvary Mater Newcastle, Newcastle
Illawarra Cancer Care Centre, Wollongong
The Canberra Hospital, Garran
Albury Base/Murray Valley Private Hospital, West Albury
Peter MacCallum Cancer Centre, East Melbourne
Austin Health, Heidelberg
Waikato Hospital, Hamilton
Andrew Love Cancer Care Centre, Geelong Hospital, Geelong
St John of God Hospital, Ballarat
Radiation Oncology - Mater Centre, South Brisbane
Princess Alexandra Hospital, Woolloongabba
Genesis Cancer Care (previously Premion), Tugun
Royal Adelaide Hospital, Adelaide
The Queen Elizabeth Hospital, Woodville
Sir Charles Gairdner Hospital, Nedlands
Launceston General Hospital, Launceston
Wellington Hospital, Wellington
Princess Margaret Hospital, Toronto
Australasian Leukaemia and Lymphoma Group
OTHER
Trans Tasman Radiation Oncology Group
OTHER